∂ÈÌ¤ÏÂÈ·: ÕÏ. ¶·‡ÏÔ˘1, ¡. √ÈÎÔÓÔÌ¿ÎË˜2, £. ¶·Ó·Óﬁ˜3, º. ¶ÂÙ˙ÂÚ›‰Ë4, ™. ¶¤ÙÚÔ‚·5
1Managing Partner BIONOVA, 2Consultant Bio Business Analysis Unit,
3Consultant technology transfer Unit and alernate NCP, 4Pharmacology Consultant 5Science Editor
Advanced Cell Technology Completes Acquisition of Mytogen, Inc.
lead to a significant increase in quality of
signed on July 31, 2007 subject to certain
life for the patient. The company applied
the treatment of heart failure will begin
closing conditions. ACTC issued a total of
Phase II clinical trials shortly, while two of
approximately 8.2 million restricted shares
and assumed certain Mytogen liabilities.
"end-of-Phase I" data and will allow
million shares of restricted common stock
with a Phase II human clinical trial.
preclinical studies. We expect to file IND's
human clinical trial for the treatment of
Phase III double-blind, placebo-controlled
years of experience in clinical trial and FDA
parallel group trial, in which approximately
III trial. The Myoblast Program may prove
stem cells. This stem cell therapy involves
particularly beneficial for patients that
and have a high risk of heart failure.
trough sitting SBP and trough sitting DBP,
medicine and we are excited to join their
cells over a period of two to three weeks.
President and Chief Scientific Officer of
active-controlled, parallel group trial, in
Mytogen, Inc. "By merging with Advanced
scarred heart tissue through the use of a
clinical trials and bring our therapies to
William M. Caldwell, IV, Chairman and CEO
safely in over 40 patients. Safety of the
"The completion of this acquisition marks
studies. While the Phase I human clinical
therapy, the clinical data from those trials
GeneGo, Inc. in Multi- Bristol-Myers Squibb to Buy Partner Adnexus Year Deal with Bristol- Therapeutics for $430 Million Myers Squibb Company
GeneGo, Inc., the leading systems biology
Bristol-Myers Squibb Company and Adnexus Therapeutics
announced today the companies have signed a definitive
agreement under which Bristol-Myers Squibb will acquire
privately held Adnexus Therapeutics, developer of a new
therapeutic class of biologics called Adnectins. The acquisition
of Adnexus will help advance Bristol-Myers Squibb's biologics
strategy across multiple therapeutic areas and includes a
Myers Squibb will have the ability to start
Phase I oncology biologic, Angiocept. Adnexus Therapeutics will become a subsidiary
of Bristol-Myers Squibb and remain based in Waltham, Massachusetts.
Under the terms of the agreement Bristol-Myers Squibb will acquire all of Adnexus'
issued and outstanding shares of capital stock and stock equivalents in an all-cash
transaction for a gross purchase price of $430 million, with the net purchase price
being $415 million after deducting Adnexus' net cash balance at closing. In addition,
there is an earn-out structure which could result in Bristol-Myers Squibb paying an
additional amount of approximately $75 million, in three increments of approximately
$25 million each, in the event certain development and regulatory milestones are
achieved. The closing of the transaction is subject to customary regulatory approvals.
Adnectins are a proprietary class of targeted biologics developed by Adnexus.
PROfusion(TM) is Adnexus' proprietary protein design engine, with which trillions of
their own internal interaction data in the
protein variations can be engineered at one time. Angiocept is an Adnectin designed
to be an anti-angiogenic drug and is currently in Phase I development.
AstraZeneca PLC to Pay Up to $310 Million for Verus Pharmaceuticals' Asthma Programs
V erus Pharmaceuticals, Inc., a pe- rsements, and a potential earn-out programs that hold the potential to help
millions of children suffering from asthma
and may positively impact their quality of
"We are excited to have completed this
respiratory primary care at AstraZeneca.
programs. Included in the transaction are
chronic childhood illness affecting almost
the North American rights to a Captisol(R)
States. Approximately 6.5 million children
rapidly expanding patient population,"
said Robert W. Keith, President and Chief
cation), a customized version of eFlow(R)
(novel nebulizer delivery device) for use
transaction allows us to refocus our time
related atopic diseases and conditions."
"AstraZeneca is proud to be a part of
cost of treating asthma in children under
S u s t a i n a b l e s c h o o l s a w a r d This document is a copy of the Sandwell Sustainable School self-evaluation audit tool and lists the evidence that will be required to become a Sustainable School. Using the on-line application form at www.sustainableschoolsaward.com schools can identify where sustainable development education takes place in teaching, good practice and manageme
R E G IS T R A T I O N D OS S I E R S A V A I L A B L E RE TAI L MA RKE T (WHOL ESAL ER S AND PH ARM AC IES) MOLECULE REFERENCE PRODUCT Acyclovir Dexketoprofen Solution for injection/Concentrate for solution for Doxazosin Fluoxetine Gabapentin Glimepiride Glucosamine Sulphate Ibuprofen-lysine Memantine Mirtazapine Pa